Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04257578 · ClinicalTrials.gov registry record · Phase 1
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
A Phase 1 study of High Grade B-Cell Lymphoma and B-Cell Non-Hodgkin Lymphoma, sponsored by University of Washington.
- Active
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT04257578 is a Phase 1 study of High Grade B-Cell Lymphoma and B-Cell Non-Hodgkin Lymphoma that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 23 participants, below the 61-participant average among 25 other High Grade B-Cell Lymphoma trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04257578, a Phase 1 study of High Grade B-Cell Lymphoma and B-Cell Non-Hodgkin Lymphoma, is active but no longer recruiting, sponsored by University of Washington.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I/II trial studies the safety of acalabrutinib and axicabtagene ciloleucel in treating patients with B-cell lymphoma. Acalabrutinib may stop the growth of tumor cells by blocking key pathways needed for cell growth. Immunotherapy with axicabtagene ciloleucel is engineered to target a specific surface antigen on lymphoma cells. Acalabrutinib may enhance the efficacy of axicabtagene ciloleucel in treating patients with B-cell lymphoma.
Conditions Studied
Interventions
- DRUG Acalabrutinib
- BIOLOGICAL Axicabtagene Ciloleucel
Study Locations (1)
Washington
- Fred Hutch/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2020-12-02 |
| Est. Completion | 2031-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04257578
The ClinicalTrials.gov registry entry for NCT04257578 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 61-participant average among 25 other High Grade B-Cell Lymphoma trials with a reported enrollment target (62% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with High Grade B-Cell Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Acalabrutinib is the first listed.
NCT04257578 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT04257578 about?
NCT04257578 is a clinical study titled "Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma". This phase I/II trial studies the safety of acalabrutinib and axicabtagene ciloleucel in treating patients with B-cell lymphoma. Acalabrutinib may stop the growth of tumor cells by blocking key pathways needed for cell growth. Immunotherapy with axicabtagene ciloleucel is engineered to target a spec...
What is the current status of trial NCT04257578?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2020-12-02. Estimated completion is 2031-03-01.
What conditions does trial NCT04257578 study?
This clinical trial studies the following conditions: High Grade B-Cell Lymphoma, B-Cell Non-Hodgkin Lymphoma, Grade 3a Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Grade 1 Follicular Lymphoma.
What interventions are being tested in trial NCT04257578?
The interventions under investigation include: Acalabrutinib (DRUG), Axicabtagene Ciloleucel (BIOLOGICAL).
Who is sponsoring clinical trial NCT04257578?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04257578 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High Grade B-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
RECRUITING · Phase 1
-
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
RECRUITING · Phase 1
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
RECRUITING · Phase 1
-
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.